Anti-D Rh0 immunoglobulin - Kamada

Drug Profile

Anti-D Rh0 immunoglobulin - Kamada

Alternative Names: Anti-D immunoglobulin - Kamada; KamRho (D) IM; KamRho (D) IV

Latest Information Update: 17 Mar 2017

Price : $50

At a glance

  • Originator Kamada
  • Class Immunoglobulins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemolytic disease of newborn; Immune thrombocytopenic purpura

Most Recent Events

  • 10 Mar 2017 Vitel Laboratorios has been acquired by OncBioMune Pharmaceuticals
  • 03 Nov 2016 KamRHO® licensed to Vitel Laboratories in Mexico before November 2016
  • 14 Jul 2016 KamRho (D) IV is still registered for Immune thrombocytopenic purpura in Argentina (Kamada Form 20-F, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top